Pdf is being generated, will be available at /media/pdfs/antimicrobial-guideline-c-difficile-infection.pdf shortly

Gastro-intestinal Infection

Download / Print Section as PDF



Download / Print Section as PDF

C. difficile Infection


Download / Print Section as PDF

General Principles

General Principles

The following guidance applies to the treatment of patients with a clinical diagnosis of Clostridioides Difficile Infection (CDI) and supportive microbiological evidence of CDI:

  • Stop unnecessary antimicrobial therapy (if possible). If an antibiotic is still essential, consider changing to one with a lower risk of causing CDI. It is preferable to use agents with as narrow spectrum as possible.  Almost all antibiotics increase the risk of CDI but clindamycin, cephalosporins, ciprofloxacin (and other fluoroquinolones) and co-amoxiclav are well-documented as having the greatest risk.
  • Avoid anti-motility medications.
  • Review proton pump inhibitor use.
  • Ensure adequate nutrition and replacement of fluid and electrolytes.
  • Record stool output daily.
  • Daily clinical review to assess for progression to severe or fulminant disease with toxic megacolon, impending perforation and shock. Urgent Surgical review is essential.
  • HCWs should wash hands with soap and water as alcohol-based hand sanitisers are less effective in removing C. difficile spores from hands.
  • Patients/ residents of a healthcare facility with potentially infectious diarrhoea (i.e. no clear alternative cause) should be isolated with Standard and Contact Precautions as soon as possible.
  • Test-of-cure or testing asymptomatic individuals is not recommended and asymptomatic carriers do not need treatment.
  • Where diarrhoea is due to laxative administration and there is no concern for infectious diarrhoea, testing for C difficile is not recommended.


Download / Print Section as PDF

Definitions

Definitions

  • Diarrhoea is defined as 3 or more loose stools, i.e. Bristol stool scale 6-7, in 24 hours.
  • Treatment response is present when the patient has resolution of diarrhoea, and has had a formed or normal stool for that patient, with maintenance of resolution for the duration of therapy and at least 48 hours after the end of treatment, and no further requirement for CDI therapy, AND parameters of disease severity (clinical, laboratory, radiological) have improved and no new signs of severe disease have developed. In all other cases, treatment is considered a failure.
  • Refractory CDI: is CDI not responding to recommended CDI antibiotic treatment, i.e. no response after 3-5 days of therapy. Refractory CDI can be part of either non-complicated or complicated CDI, which are described below.
  • Recurrence: is present when CDI recurs within 8 weeks after a previous episode, provided the symptoms from the previous episode resolved after completion of initial treatment. It is not feasible to distinguish recurrence due to relapse (renewed symptoms from already present CDI) from recurrence due to reinfection in daily practice because genotyping is not readily available.
  • Severe CDI: is characterized by one of the following factors at presentation:
    • Fever, i.e. core body temperature greater than 38.5°C,
    • Marked leucocytosis, i.e. leucocyte count greater than 15 x 10 9 /L, and
    • Rise in serum creatinine, i.e. more than 50% above the baseline.
    • Additional supporting factors, when available are distension of the large intestine, pericolonic fat stranding or colonic wall thickening (including low-attenuation mural thickening) at imaging.
  • Severe-complicated CDI (or fulminant CD) : is defined by the presence of one of the following factors that needs to be attributed to CDI:
    • Hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, bowel perforation or any fulminant course of disease (i.e. rapid deterioration of the patient).


Download / Print Section as PDF

Initial Episode & First Recurrence of C. difficile Infection (CDI)

Initial Episode & First Recurrence of C. difficile Infection (CDI)

Source: HSE AMRIC Clostridioides difficile infection treatment guidance (version 2.0) 2023

Additional Comments:

  • Vancocin® (Vancomycin) Matrigel Capsules 125 mg are now included on the GMS Reimbursement List (i.e. a High Tech Prescription is no longer required) and thus any prescriber is able to prescribe it in line with treatment options set out in the CDI treatment guidance.
  • Oral vancomycin is not absorbed from the GIT and therefore should never be used as systemic therapy. Its sole use is in the treatment of CDI. Therapeutic drug monitoring is not required.
  • Fidaxomicin has not been tested in pregnant or breastfeeding women or in patients with a history of inflammatory bowel disease. It is also a reserve agent, and thus must be discussed with Clinical Microbiologist prior to prescribing.


Download / Print Section as PDF

Multiple (≥2nd) Recurrence CDI

Multiple (≥2nd) Recurrence CDI

Please discuss with Clinical Microbiologist or Infectious Diseases.

For non-severe & severe CDI, treatment options are:

  • Fidaxomicin 200mg BD 10 days (if initial treatment with oral vancomycin) or
  • Vancomycin 125mg QDS orally 10 days, or
  • Vancomycin tapering regimen:

125mg orally QDS for two weeks

125mg orally BD for one week

125mg orally OD for one week

125mg orally every 48 hours for one week

125mg orally every 72 hours for one week

  • Early surgical review for severe CDI
  • Consider referral for faecal microbiota transplantation if available (MDT discussion required)

For severe-complicated/fulminant CDI:

  • Vancomycin 500mg QDS oral PLUS Metronidazole 500mg TDS IV
  • Urgent surgical review essential
  • In patients with ileus (or any condition preventing vancomycin reaching the colon) and not responding to enteral therapy, consider administering intracolonic vancomycin. This carries a risk of colonic perforation and should only be performed by personnel trained in administering enemas.

Other adjunctive therapies such as Tigecycline IV may be considered in severe, severe-complicated/fulminant CDI in addition to standard therapy. Please discuss with Clinical Microbiologist or Infectious Diseases.


Download / Print Section as PDF

References

References

  1. HSE AMRIC Clostridioides difficile infection treatment guidance (version 2.0) 2023
  2. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. https://doi.org/10.1016/j.cmi.2021.09.038
  3. NICE Guideline [NG199] Clostridioides difficile infection: antimicrobial prescribing. 2021. https://www.nice.org.uk/guidance/ng199
  4. IDSA and SHEA: 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clinical Infectious Diseases. 2021. https://doi.org/10.1093/cid/ciab549


Download / Print Section as PDF

Acute Gastroenteritis

Acute Gastroenteritis

General points

  • Infectious diarrhoea is usually self-limiting and does not require antimicrobials.
  • Fluid and electrolyte replacement is essential.
  • Avoid anti-motility agents.
  • If immunocompromised or if symptoms are severe (e.g. signs of sepsis) or prolonged discuss with clinical microbiology advisory team.
  • Infection Control: All patients with unexplained diarrhoea should be isolated in a single room with ensuite toilet facilities and standard and contact transmission based precautions.
  • Send stool specimen to microbiology laboratory for investigation.

Specific pathogens

Salmonella gastroenteritis : Usually self -limiting infection. Antibiotics indicated in severe or invasive infection, immunocompromised hosts and those at risk of complicated infection (extremes of age, cardiac or endovascular devices, prosthetic joints).  Review with susceptibility test results and discuss with microbiology.

Campylobacter spp : Self-limiting infection in most people. If severe or prolonged (> 7 days) symptoms- Azithromycin 500mg once daily PO x 3 days. Discuss with clinical microbiology advisory team if immunocompromised or signs of sepsis.

Shigella spp.: Usually antimicrobials not required if symptoms resolved. Severe infection, systemically ill or immunocompromised patients and those at high risk of contributing to secondary spread (eg. food handlers, childcare workers) should be treated: Azithromycin 500mg once daily PO x 3 days OR Ceftriaxone 1-2g once daily IV. Discuss with microbiology and review with susceptibility test results.

VTEC eg. E. coli 0157 : Antimicrobials not recommended due to potential for increased toxin production. Caution re development of Haemolytic Uraemic Syndrome (HUS).

Giardia : Metronidazole 400mg TDS PO x 5 days. Discuss with clinical microbiology advisory team if immunocompromised or pregnant.

Viral causes eg. Norovirus, Rotavirus, and Adenovirus: No antimicrobials required.


Download / Print Section as PDF

Helicobacter pylori

Helicobacter pylori

Please refer to HSE Antimicrobial Prescribing Guideline